Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro
The published work (Segatto et al. 2024 Front. Oncol., 25 February 2024) discusses the development of a novel urothelial carcinoma cell line from Oncopigs®, Sus Clinicals’ genetically modified porcine model. The aim was to create a reliable in vitro model for bladder cancer research. The researchers successfully demonstrated that these Oncopig® bladder cancer cell lines mimic human bladder cancer cell responses to commonly used chemotherapeutic agents (cisplatin, doxorubicin, and gemcitabine).
Read articleEffect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma
In a groundbreaking study, scientists have used advanced genetic editing techniques (CRISPR) to create customized porcine models for studying liver cancer, specifically hepatocellular carcinoma (HCC). The researchers focused on two key genes, AXIN1 and ARID1A, which are frequently mutated in human liver cancer, and successfully replicated these mutations in pigs. This work lays the foundation for development and utilization of genetically-tailored porcine HCC models for in vivo testing of novel therapeutic approaches in a clinically-relevant large animal model.
Read articlePorcine Cancer Models: Potential Tools to Enhance Cancer Drug Trials
The amount of time and money invested into cancer drug research, development, and clinical trials has continually increased over the past few decades. Despite record high cancer drug approval rates, cancer remains a leading cause of death. This suggests the need for more effective tools to help bring novel therapies to clinical practice in a timely manner.
Read articleTranslating Human Cancer Sequences Into Personalized Porcine Cancer Models
The global incidence of cancer is rapidly rising, and despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide. The authors explain that by creating pig models that mirror patients' genetic profiles, researchers can improve the predictability of treatment outcomes and accelerate progress in cancer research and treatment.
Read articleOf Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Cancer has recently surpassed cardiovascular diseases as the leading cause of death worldwide. The increasing cancer incidence combined with the emergence of improved therapeutic strategies has driven research into fields such as how the immune system Influences cancer development and progression. This article reviews various animal models, and explains the benefits of porcine-based preclinical research.
Read articleKRASG12D And TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus Scrofa Pigs
This article details development of the first large animal model of pancreatic carcinogenesis and may allow for insight into new avenues of translational research not before possible in rodents. By developing a porcine model via the Oncopig platform that closely mimics human pancreatic ductal adenocarcinoma (PDAC), researchers can now explore new treatment modalities, surgical interventions, and radiological techniques that were previously unfeasible in mouse models.
Read articleThe Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. This article covers how a transgenic pig model can offer a controlled and predictable platform for studying cancer and testing new therapies.
Read article